Press releases

11th November 2024

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types

Gene expression data shows upregulation of innate immunity pathways

Tumor regressions observed at all dose levels, 60-200 mg TIW

9th October 2024

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium

STC-15 is the first METTL3 inhibitor to enter clinical development

Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients

17th June 2024

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases

3rd June 2024

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients. Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies.

24th May 2024

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development. Clinical data will include safety, pharmacology, target modulation, and clinical activity.